A majority of deaths from Friedreich's ataxia are associated with heart complications. A new treatment years in the making could provide some much-needed relief.
Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.
The risk associated with under-recognized CKD emerged early, highlighting the need for screening soon after a CAD diagnosis so that cardio-renal protective drugs can be started much earlier.
The randomized, double-blinded phase 3 study revealed gadopiclenol to be noninferior to gadobutrol for all qualitative visualization parameters as rated by all blinded readers involved in the trial.
Researchers at the National Institute of Standards and Technology (NIST) are working on developing measurements that will provide better insight into soft tissue properties visualized on portable MRI images.
The program leverages the in-context learning abilities of large language models to generate report summaries using domain-specific, individualized data relative to radiology.
The FDA Circulatory System Devices Panel is set to review the PMA submissions for the ReCor and Medtronic renal denervation systems to treat patients with uncontrolled hypertension.
Jonathan Lindner, MD, offers an update on the use of echocardiography and bubble contrast agents in a therapy role to help revascularize STEMI patients and increase drug and gene delivery.
